91Â鶹ÌìÃÀÖ±²¥

Huntsman Cancer Institute (HCI) predoctoral fellow Prasoona Karra, MS, was selected to receive the National Cancer Institute (NCI) . These highly competitive awards are presented to "outstanding predoctoral researchers" and are designed to support them in the late stages of PhD training through transition to postdoctoral position. The award provides up to six years of funding. Only a handful are awarded each year from the NCI.

Karra’s award will be used to advance her research program in understanding how changes to metabolism in obesity can influence risk of cancer, as well as survival after a cancer diagnosis.

Karra’s primary mentor, , MPH, HCI researcher and (U of U) assistant professor of nutrition and integrative physiology, says, "Prasoona’s receipt of this award recognizes her as a promising early career researcher who is tackling critical, unanswered questions that could have a high impact on obesity-related cancers in Utah and beyond."

"I am delighted for Prasoona to receive this award," says one of Karra’s co-mentors, HCI researcher and U of U assistant professor of population health sciences. "Her innovative project will help improve our understanding of the role of metabolic dysfunction in cancer risk and prognosis. Having been an international student myself, I know that the opportunities to get federal funding are limited, which makes this achievement even more remarkable."

Karra’s research will focus on metabolic health and 13 obesity-related cancer types. Using data from a large group of adult Utahns followed over decades, Karra will evaluate whether people in the normal weight range who have abnormal metabolic markers, like blood glucose, have similar obesity-related cancer risk to those who are obese. She will also look at how a new diagnosis of type 2 diabetes after cancer can affect survival outcomes in women.

"I feel honored to receive this award," says Karra. "My ultimate research goal is to work with doctors to identify individuals at risk of cancer using sophisticated metabolic data, and help these patients reduce their cancer risk."